Prognostic differences among PCA-2 phenotypes have not been reported, but patients with peripheral neuropathy with co-existing PCA-2 and ANNA1 antibodies and/or CRMP5 antibodies have a lower survival rate (9). Here, DPYSL5 is linked to peripheral neuropathy.